Subject Index

A
Auromomycin 41
Antineoplastic Activity 27
Arotinoids 27

B
bis(Guanylhydrazone) 31
Breast Cancer 37

C
CDDP-induced 11
Chemoimmunotherapy 5
Chemotherapy 37
Cross Resistance 15

D
Dexamethasone 11
DNA Breakage 41
Doxorubicin 15, 65

E
Etoposide 175
– and Teniposide in vitro 113

F
Ftorafur Metabolism 55

G
Gastric Cancer 5

H
Hematoxicity 41
Hodgkin's and Non-Hodgkin's Lymphoma 175

I
In vitro 21

M
Methotrexate 61
Methylglyoxal 31

O
O,p'-DDD Blood Level 51

P
Podophyllotoxin 93, 99
– Development 93
– Derivatives 99
Predictive Test 1
Protein Binding 61

R
Radioimmunoassay 117

S
Sensitivity Testing 21

V
VM26 73
– ALL in Children 169
– Clinical Pharmacology 133
– Malignant Hematological Diseases 173
– Pharmacokinetics 151
– – in Children 147
– Phase I and II Studies 87
VP16-213 73
– Activity of 81
– Acute Nonlymphocytic Leukemia 161
– Adriamycin 215, 231
– Breast Cancer 223, 231
– Chloroquine 123
– Choriocarcinoma 211
– *cis*-Platin 181, 203, 215
– Clinical Pharmacology 133
– Continous Infusion 157
– Cyclophosphamide 181, 187, 209
– Doxorubicin 187
– Etoposide 195
– Germ Cell Tumors 215
– in Advanced Breast Cancer 227
– in Combination 199
– Lung Cancer 209
– Mitomycin-C 227
– Pharmacokinetics 127, 141, 151
– – in Children 147
– Podophyllotoxin 103
– Radiotherapy 181
– Small Cell Lung Cancer 179, 181, 187, 195, 199, 203, 205
– Testicular Teratoma 219
– VAC 195
Vomiting 11